5 completed, 2 terminated. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Terminated 2 |
Follow fevipiprant: new trials by email Literature Review of fevipiprant trials Research Report on fevipiprant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo - Nasal Polyps | Phase 3 | Completed | Novartis Pharmaceuticals | 98 | 2019-03-26 | 2021-10-11 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 604 | 2018-12-13 | 2021-10-11 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 675 | 2017-11-01 | 2026-01-13 |
| Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 704 | 2017-10-31 | 2026-01-13 |
| Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment QAW039 150 mg, QAW039 450 mg, Placebo - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 2538 | 2017-03-21 | 2020-10-12 |
| Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 894 | 2015-12-11 | 2026-10-07 |
| Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 877 | 2015-12-03 | 2021-05-03 |
Asthma (7) · Bronchial Diseases (2) · Dyspnea (2) · Lung Diseases (2) · Respiratory Hypersensitivity (2) · Hypersensitivity (1) · Immune System Diseases (1) · Lung Diseases, Obstructive (1) · Nasal Polyps (1) · Nose Diseases (1) · Respiratory Tract Diseases (1)
United States (7) · Argentina (6) · Germany (6) · Hungary (5) · Spain (5) · Belgium (4) · Canada (4) · Czechia (4) · Greece (4) · Philippines (4) · Russia (4) · Slovakia (4) · Brazil (3) · Bulgaria (3) · Colombia (3)
2015 (2), 2017 (2), 2018 (2), 2016 (1)